Windtree Therapeutics Targets $520M Funding to Boost BNB Treasury Holdings

Nasdaq-listed biotech company Windtree Therapeutics announced plans to raise up to $520 million, with 99% of proceeds dedicated to expanding its BNB cryptocurrency reserves. The firm secured a $500 million equity line of credit and a separate $20 million stock purchase agreement, pending shareholder approval to increase authorized shares.

"This positions us to execute our BNB treasury strategy," stated CEO Jed Latkin, positioning the move as part of broader financial stabilization efforts. The announcement highlights increasing corporate interest in digital asset diversification, with Windtree's biotech focus making its crypto pivot particularly noteworthy.

Windtree has partnered with an undisclosed crypto exchange to facilitate BNB acquisitions. The company's shares (Nasdaq: WINT) will see funding facilitated through Build and Build Corp as the counterparty to the stock purchase agreement.